COVID-19 'Pandemic'

Twin_Moose

Hall of Fame Member
Apr 17, 2017
18,401
4,148
113
Twin Moose Creek
In 2021 Covid 19 has been around & had more time to spread and mutate than in 2020.

A large % of the deaths are in those partly or fully vaccinated. Is the large number larger than the deaths in the unvaccinated?

Is that large percentage of deaths in the vaccinated a significantly smaller %’age than those deaths in the unvaccinated?

If the deaths (I’m just spitball in here and guessing like a politician) are split 85% unvaccinated & 15% vaccinated, what if anything does that tell us? Maybe that this shitty Chinese released disease would be way worse with more deaths if there where no vaccines at all?

We’re in a 24/7 news cycle so we hear & see & read everything eventually, including every adverse reaction to this vaccine or whatever you wish to call it, even if that’s one in 10,000 or whatever the number happens to be.

I don’t want to get this pestilence and I sure as shit wouldn’t want to have on my conscience giving it to someone if I could have avoided it with a few precautions, & if I get it I’d like to know I’ve done everything I can to minimize its negative outcome. It’s a crapshoot & I get it. Unproven vaccine, weigh & measure the options and outcomes, then pull the trigger & get it done. If I get Covid & kick the bucket, then so be it and I’ve done all that I could in advance. Done deal.

I totally dislike the idea of ‘mandatory’ anything including ‘mandatory’ vaccinations, but I CHOSE to get mine to protect my spouse & children & grandchildren & myself if at all possible.
  1. Former CDC Director Gives Alarming Statistic on Fully ...

    2021-10-19 · Dr. Robert Redfield just told @MarthaMacCallum on @Foxnews that 40% of the recent Covid deaths in the state of Maryland were among people who are fully vaccinated.




    Hospitalized or fatal COVID-19 vaccine breakthrough cases reported to CDC as of October 18, 2021

    As of October 18, 2021, more than 189 million people in the United States had been fully vaccinated against COVID-19.

    During the same time, CDC received reports from 50 U.S. states and territories of 41,127 patients with COVID-19 vaccine breakthrough infection who were hospitalized or died

    Dr. Naomi Wolf: CDC COVID Data Is Actually Farmed Out to Non-Profit with Ties to Gates (VIDEO)​

    By Jim Hoft
    Published October 23, 2021 at 9:55am
    174 Comments

    Dr. Naomi Wolf dropped this bomb, “The most shocking thing I shared with you guys last time is that the CDC data is actually farmed out to a non-profit with Gates’ ties. Half a billion dollars from the CAREs Act to those people. They’re not confined by rules about data presentation which is probably illegal. And they have a vested interest.”



 

pgs

Hall of Fame Member
Nov 29, 2008
22,076
3,180
113
B.C.
  1. Former CDC Director Gives Alarming Statistic on Fully ...

    2021-10-19 · Dr. Robert Redfield just told @MarthaMacCallum on @Foxnews that 40% of the recent Covid deaths in the state of Maryland were among people who are fully vaccinated.




    Hospitalized or fatal COVID-19 vaccine breakthrough cases reported to CDC as of October 18, 2021

    As of October 18, 2021, more than 189 million people in the United States had been fully vaccinated against COVID-19.

    During the same time, CDC received reports from 50 U.S. states and territories of 41,127 patients with COVID-19 vaccine breakthrough infection who were hospitalized or died

    Dr. Naomi Wolf: CDC COVID Data Is Actually Farmed Out to Non-Profit with Ties to Gates (VIDEO)​

    By Jim Hoft
    Published October 23, 2021 at 9:55am
    174 Comments

    Dr. Naomi Wolf dropped this bomb, “The most shocking thing I shared with you guys last time is that the CDC data is actually farmed out to a non-profit with Gates’ ties. Half a billion dollars from the CAREs Act to those people. They’re not confined by rules about data presentation which is probably illegal. And they have a vested interest.”


Yet Nick is telling us that only the unvaccinated are dying .
 
  • Wow
Reactions: Twin_Moose

spaminator

Hall of Fame Member
Oct 26, 2009
29,527
1,446
113
Antidepressant drug shows promise in treating COVID-19: Study
The drug has been in use since 1990 and works by helping to restore the balance of serotonin in the brain

Author of the article:Washington Post
Washington Post
Adela Suliman
Publishing date:Oct 28, 2021 • 17 hours ago • 2 minute read • Join the conversation
A young woman taking a pill.
A young woman taking a pill. PHOTO BY STOCK ART /Getty Images
Article content
A common drug used to treat depression, fluvoxamine, has shown promise in the treatment of early COVID-19, scientists said.

Advertisement
STORY CONTINUES BELOW

Article content
The research was published in the Lancet Global Health journal on Wednesday and based off a large clinical trial that took place across 11 cities in Brazil from January to August 2021. It looked at high-risk symptomatic Brazilian adults who had covid-19 and were at risk of severe illness because of other health problems.


The research found that “treatment with fluvoxamine (100 mg twice daily for 10 days) among high-risk outpatients with early diagnosed COVID-19 reduced the need for hospitalisation.”

Just under 1,500 individuals took part in the trial — about half of whom received the drug and the other half a placebo. The average age of participants was 50 and almost 60% were women, according to the study. The participants were tracked for four weeks and took the pills for 10 days while at home.

Advertisement
STORY CONTINUES BELOW

Article content
In the group that took the drug, 11% needed hospitalization or an extended emergency room stay, compared to 16% of those who took the placebo.

“Fluvoxamine is the only treatment that, if administered early, can prevent COVID-19 from becoming a life-threatening illness,” said study co-author Dr. Edward Mills of McMaster University in Ontario in August. “It could be one of our most powerful weapons against the virus and its effectiveness is one of the most important discoveries we have made since the pandemic began.”


The drug has been in use since 1990 and is typically used to treat depression and obsessive-compulsive disorder. It is known as a selective serotonin reuptake inhibitor and works by helping to restore the balance of serotonin in the brain.

It is also relatively cheap, costing about $4 for a 10 day course compared to antibody IV treatments that cost about $2,000. Mills said the drug could be a “game-changer” for poorer nations or those with low vaccination rates.

The TOGETHER Trial group, which was responsible for the research, said they had shared the findings with the World Health Organization and the U.S. National Institutes of Health.
 

spaminator

Hall of Fame Member
Oct 26, 2009
29,527
1,446
113
COVID-strained auditor general's office played online games during work hours
Author of the article:postmedia News
Publishing date:Nov 04, 2021 • 13 hours ago • 1 minute read • 9 Comments
Auditor General Karen Hogan listens to a question during a news conference in Ottawa, Wednesday May 26, 2021.
Auditor General Karen Hogan listens to a question during a news conference in Ottawa, Wednesday May 26, 2021. PHOTO BY ADRIAN WYLD /The Canadian Press
Article content
Managers in Auditor General Karen Hogan’s office spent staff time playing online puzzle games as a “team-building activity,” according to Blacklock’s Reporter , which said officials confirmed the report.

Advertisement
STORY CONTINUES BELOW

Article content
Blacklock’s said Hogan had complained to MPs her office was under “tremendous challenges” due to COVID and budget constraints.


“This was not an office-wide activity,” said Vincent Frigon, spokesperson for Hogan. “It was a team-building activity for one team.”

Frigon said only 17 of 567 employees were invited to the Zoom puzzle game, which was played during working hours.

“Escape games are designed to have participants work together to complete a mission,” said Frigon. “Their value as a team-building tool is well established. They develop and enhance teamwork, collaborative problem solving and communications skills.

“A virtual escape room is a web-based experience,” he explained. “Participants join the room via the platform and work together in a fixed amount of time to gather the information needed to complete specific steps in a set order to exit the room before the clock runs out.”

Hogan had said in an Oct. 20, 2020 report to Parliament that her office was stretched thin with pandemic safety precautions and an $87.6 million budget. “The pandemic has presented tremendous challenges to our operations,” Hogan wrote in a Departmental Results Report.

“Our staff has been busy reimagining the ‘new normal’ of our audit work, acquiring new tools and exploring new formats for engaging and communicating with staff at a distance and developing new ways to support learning,” wrote Hogan. The report did not mention online gaming, Blacklock’s said.
 

spaminator

Hall of Fame Member
Oct 26, 2009
29,527
1,446
113
Britain approves Merck's COVID-19 pill in world first
Author of the article:Reuters
Reuters
Publishing date:Nov 04, 2021 • 21 hours ago • 4 minute read • Join the conversation
An experimental COVID-19 treatment pill called molnupiravir being developed by Merck & Co Inc and Ridgeback Biotherapeutics LP, is seen in this undated handout photo released by Merck & Co Inc and obtained by Reuters May 17, 2021.
An experimental COVID-19 treatment pill called molnupiravir being developed by Merck & Co Inc and Ridgeback Biotherapeutics LP, is seen in this undated handout photo released by Merck & Co Inc and obtained by Reuters May 17, 2021. PHOTO BY MERCK & CO INC /via REUTERS
Article content
Britain on Thursday became the first country in the world to approve a potentially game-changing COVID-19 antiviral pill jointly developed by U.S.-based Merck and Ridgeback Biotherapeutics, in a boost to the fight against the pandemic.

Advertisement
STORY CONTINUES BELOW

Article content
Britain’s Medicines and Healthcare products Regulatory Agency (MHRA) recommended the drug, molnupiravir, for use in people with mild to moderate COVID-19 and at least one risk factor for developing severe illness, such as obesity, older age diabetes, and heart disease.


It will be administered as soon as possible following a positive COVID-19 test and within five days of the onset of symptoms, the regulator said, citing clinical data.

The green light is the first for an oral antiviral treatment for COVID-19 and the first for a COVID-19 drug that will be administered widely in the community. U.S. advisers will meet this month to vote on whether molnupiravir should be authorized.

Treatments to tackle the pandemic, which has killed more than 5.2 million people worldwide, have so far focused mainly on vaccines. Other options, including Gilead’s infused antiviral remdesivir and generic steroid dexamethasone, are generally only given after a patient has been hospitalized.

Advertisement
STORY CONTINUES BELOW

Article content
Merck’s Molnupiravir has been closely watched since data last month showed it could halve the chances of dying or being hospitalized for those most at risk of developing severe COVID-19 when given early in the illness.

Molnupiravir, which will be branded as Lagevrio in Britain, is designed to introduce errors into the genetic code of the coronavirus that causes COVID-19 and is taken twice a day for five days.

Professor Stephen Powis, national medical director for the National Health Service (NHS) in England, said the drug would be administered to patients at higher risk of complications as Britain heads into one of the most challenging winters ever.

A wider rollout will follow if it is clinically and cost effective in reducing hospitalizations and death, he added.

Advertisement
STORY CONTINUES BELOW

Article content
“We are now working across government and the NHS to urgently get this treatment to patients initially through a national study so we can collect more data on how antivirals work in a mostly vaccinated population,” UK vaccines minister Maggie Throup told parliament.


PRESSURES

The speedy approval in Britain, which was also the first Western country to approve a COVID-19 vaccine, comes as it struggles to tame soaring infections.

Britain has about 40,000 daily cases of COVID-19, according to the latest seven-day average. That is second only to the roughly 74,000 a day in the United States, which has five times more people, and has fueled criticism of the government’s decision to abandon most pandemic-related restrictions

Advertisement
STORY CONTINUES BELOW

Article content
Data released on Wednesday night showed COVID-19 prevalence in England hit its highest level on record last month, led by a high numbers of cases in children and a surge in the south-west of the country.

Pressure is growing on the government to implement its “Plan B” aimed at protecting the NHS from unsustainable demands, involving mask mandates, vaccine passes and work-from-home orders.

Many other big economies, including Germany, France and Israel, have either retained some basic COVID-19 measures like mask mandates or reintroduced them in response to rising cases.

The UK government has said its focus remains on administering vaccine boosters and inoculating 12 to 15-year-olds.

“With no compromises on quality, safety and effectiveness, the public can trust that the MHRA has conducted a robust and thorough assessment of the data (on molnupiravir),” MHRA chief June Raine said in a statement.

Advertisement
STORY CONTINUES BELOW

Article content
Last month, Britain agreed a deal with Merck to secure 480,000 courses of molnupiravir.

Professor Penny Ward, an independent pharmaceutical physician, welcomed the approval, but said the NHS needed to outline its plans for rollout and cautioned that supplies were likely to be tight given the strong global demand.

“Comments made by Mr Javid today suggest that it may be made available via a clinical trial, presumably to investigate its effectiveness in vaccinated patients with breakthrough infections, as the original study incorporated unvaccinated adults,” she said.

If given to everyone becoming unwell, the nearly half a million courses would not last very long given the more than 40,000 current daily case rate, she said.

Advertisement
STORY CONTINUES BELOW

Article content
TREATMENT RACE

In a separate statement, Merck said it expected to produce 10 million courses of the treatment by the end of this year, with at least 20 million set to be manufactured in 2022.

The U.S. based drugmaker’s shares were up 2.1% at $90.54 before the market open.

Pfizer and Roche are also racing to develop easy-to-administer antiviral pills for COVID-19. Pfizer last month began a large study of its oral antiviral drug for the prevention of COVID-19 in people exposed to the coronavirus.

Merck’s molnupiravir is also being studied in a late-stage trial for preventing infection.

Viral sequencing done so far has shown molnupiravir is effective against all variants of the coronavirus, Merck has said, including the more-infectious Delta, which is responsible for the worldwide surge in hospitalizations and deaths recently.

While it is not yet clear when Merck will deliver doses to Britain, the company has said it is committed to providing timely access to its drug globally with plans for tiered pricing aligned with a country’s ability to pay.

Merck is also in talks with generic drugmakers about expanding manufacturing licenses to build supply of the treatment.

Antibody cocktails like those from Regeneron and Eli Lilly have also been approved for non-hospitalized COVID-19 patients, but have to be given intravenously.
 

spaminator

Hall of Fame Member
Oct 26, 2009
29,527
1,446
113
Was man who died of COVID-19 dissected in front of live audience?
Author of the article:postmedia News
Publishing date:Nov 04, 2021 • 13 hours ago • 1 minute read • Join the conversation
Was the body of an elderly man who had died from COVID-19 dissected in front of a live audience?
Was the body of an elderly man who had died from COVID-19 dissected in front of a live audience? PHOTO BY FILES /Getty Images
Article content
Was the body of an elderly man who had died from COVID-19 dissected in front of a live audience?

Advertisement
STORY CONTINUES BELOW

Article content
That’s what Seattle NBC outlet King 5 claims .


It was reportedly a pay-per-view event in Portland, Orgeon last month.

The man was identified as David Saunders, 98.

His body had been donated for medical research, but somehow sold to the Oddities and Curiosities Expo, KING 5 reported.

As the story goes, Saunders’ body was donated to Med Ed Labs, based in Las Vegas.

The founder of DeathScience.org, Jeremy Ciliberto, said he partnered with the Odditites and Curiosities Expo to buy cadavers, according to KING 5.

“The Oddities and Curiosities Expo travels across the country showcasing “taxidermy, preserved specimens, original artwork, horror/halloween inspired pieces, antiques, handcrafted oddities, quack medical devices, creepy clothing, odd jewelry, skulls/bones, funeral collectibles,” its website states.

Attendees to the pay-per-view were charged $500 to watch.

“This is not a sideshow. This is very professional ” Ciliberto told KING 5.

But Saunders’ family disagreed and said they did not give consent.

Ciliberto did not immediately respond to a request for comment by PEOPLE.
 

Ron in Regina

"Voice of the West" Party
Apr 9, 2008
15,784
1,188
113
Regina, Saskatchewan
I’m assuming when you donate your body it’s with the idea that you might be saving or improving someone’s life with your donated eyes or kidneys, & not becoming a pay-per-view sideshow circus freak. The concept of dignity is lacking in this situation.
 
Last edited:

pgs

Hall of Fame Member
Nov 29, 2008
22,076
3,180
113
B.C.
Britain approves Merck's COVID-19 pill in world first
Author of the article:Reuters
Reuters
Publishing date:Nov 04, 2021 • 21 hours ago • 4 minute read • Join the conversation
An experimental COVID-19 treatment pill called molnupiravir being developed by Merck & Co Inc and Ridgeback Biotherapeutics LP, is seen in this undated handout photo released by Merck & Co Inc and obtained by Reuters May 17, 2021.
An experimental COVID-19 treatment pill called molnupiravir being developed by Merck & Co Inc and Ridgeback Biotherapeutics LP, is seen in this undated handout photo released by Merck & Co Inc and obtained by Reuters May 17, 2021. PHOTO BY MERCK & CO INC /via REUTERS
Article content
Britain on Thursday became the first country in the world to approve a potentially game-changing COVID-19 antiviral pill jointly developed by U.S.-based Merck and Ridgeback Biotherapeutics, in a boost to the fight against the pandemic.

Advertisement
STORY CONTINUES BELOW

Article content
Britain’s Medicines and Healthcare products Regulatory Agency (MHRA) recommended the drug, molnupiravir, for use in people with mild to moderate COVID-19 and at least one risk factor for developing severe illness, such as obesity, older age diabetes, and heart disease.


It will be administered as soon as possible following a positive COVID-19 test and within five days of the onset of symptoms, the regulator said, citing clinical data.

The green light is the first for an oral antiviral treatment for COVID-19 and the first for a COVID-19 drug that will be administered widely in the community. U.S. advisers will meet this month to vote on whether molnupiravir should be authorized.

Treatments to tackle the pandemic, which has killed more than 5.2 million people worldwide, have so far focused mainly on vaccines. Other options, including Gilead’s infused antiviral remdesivir and generic steroid dexamethasone, are generally only given after a patient has been hospitalized.

Advertisement
STORY CONTINUES BELOW

Article content
Merck’s Molnupiravir has been closely watched since data last month showed it could halve the chances of dying or being hospitalized for those most at risk of developing severe COVID-19 when given early in the illness.

Molnupiravir, which will be branded as Lagevrio in Britain, is designed to introduce errors into the genetic code of the coronavirus that causes COVID-19 and is taken twice a day for five days.

Professor Stephen Powis, national medical director for the National Health Service (NHS) in England, said the drug would be administered to patients at higher risk of complications as Britain heads into one of the most challenging winters ever.

A wider rollout will follow if it is clinically and cost effective in reducing hospitalizations and death, he added.

Advertisement
STORY CONTINUES BELOW

Article content
“We are now working across government and the NHS to urgently get this treatment to patients initially through a national study so we can collect more data on how antivirals work in a mostly vaccinated population,” UK vaccines minister Maggie Throup told parliament.


PRESSURES

The speedy approval in Britain, which was also the first Western country to approve a COVID-19 vaccine, comes as it struggles to tame soaring infections.

Britain has about 40,000 daily cases of COVID-19, according to the latest seven-day average. That is second only to the roughly 74,000 a day in the United States, which has five times more people, and has fueled criticism of the government’s decision to abandon most pandemic-related restrictions

Advertisement
STORY CONTINUES BELOW

Article content
Data released on Wednesday night showed COVID-19 prevalence in England hit its highest level on record last month, led by a high numbers of cases in children and a surge in the south-west of the country.

Pressure is growing on the government to implement its “Plan B” aimed at protecting the NHS from unsustainable demands, involving mask mandates, vaccine passes and work-from-home orders.

Many other big economies, including Germany, France and Israel, have either retained some basic COVID-19 measures like mask mandates or reintroduced them in response to rising cases.

The UK government has said its focus remains on administering vaccine boosters and inoculating 12 to 15-year-olds.

“With no compromises on quality, safety and effectiveness, the public can trust that the MHRA has conducted a robust and thorough assessment of the data (on molnupiravir),” MHRA chief June Raine said in a statement.

Advertisement
STORY CONTINUES BELOW

Article content
Last month, Britain agreed a deal with Merck to secure 480,000 courses of molnupiravir.

Professor Penny Ward, an independent pharmaceutical physician, welcomed the approval, but said the NHS needed to outline its plans for rollout and cautioned that supplies were likely to be tight given the strong global demand.

“Comments made by Mr Javid today suggest that it may be made available via a clinical trial, presumably to investigate its effectiveness in vaccinated patients with breakthrough infections, as the original study incorporated unvaccinated adults,” she said.

If given to everyone becoming unwell, the nearly half a million courses would not last very long given the more than 40,000 current daily case rate, she said.

Advertisement
STORY CONTINUES BELOW

Article content
TREATMENT RACE

In a separate statement, Merck said it expected to produce 10 million courses of the treatment by the end of this year, with at least 20 million set to be manufactured in 2022.

The U.S. based drugmaker’s shares were up 2.1% at $90.54 before the market open.

Pfizer and Roche are also racing to develop easy-to-administer antiviral pills for COVID-19. Pfizer last month began a large study of its oral antiviral drug for the prevention of COVID-19 in people exposed to the coronavirus.

Merck’s molnupiravir is also being studied in a late-stage trial for preventing infection.

Viral sequencing done so far has shown molnupiravir is effective against all variants of the coronavirus, Merck has said, including the more-infectious Delta, which is responsible for the worldwide surge in hospitalizations and deaths recently.

While it is not yet clear when Merck will deliver doses to Britain, the company has said it is committed to providing timely access to its drug globally with plans for tiered pricing aligned with a country’s ability to pay.

Merck is also in talks with generic drugmakers about expanding manufacturing licenses to build supply of the treatment.

Antibody cocktails like those from Regeneron and Eli Lilly have also been approved for non-hospitalized COVID-19 patients, but have to be given intravenously.
Apparently it is similar to ivermectin. Who would have thunk it .
 

spaminator

Hall of Fame Member
Oct 26, 2009
29,527
1,446
113
Gene linked to doubling risk of COVID-19 death found by UK scientists
Author of the article:Reuters
Reuters
Publishing date:Nov 05, 2021 • 23 hours ago • 1 minute read • Join the conversation
Coronavirus and DNA, virus mutation.
Coronavirus and DNA, virus mutation. PHOTO BY FILE PHOTO /Getty Images
Article content
British scientists have identified a gene that doubles the risk of dying from COVID-19, providing new insights into why some people are more susceptible to the disease than others, while opening up possibilities for targeted medicine.

Advertisement
STORY CONTINUES BELOW

Article content
Around 60% of people with South Asian ancestry carry the high-risk gene, researchers at Oxford University said on Friday, adding the discovery partly explains the high number of deaths seen in some British communities, and the effect of COVID-19 in the Indian subcontinent.

Canadian actor Scott Speedman is a first-time father

Trackerdslogo
The scientists found that the increased risk is not because of a difference in genetic coding of the proteins, but because of differences in the DNA that makes a kind of “switch” to turn a gene on.

That genetic signal is likely to affect cells in the lung, while a higher risk version of the identified gene, called LZTFL1, possibly prevents the cells lining airways and the lungs from responding to the virus properly.


However, the higher risk version gene does not affect the body’s immune system that makes antibodies to fight off infections, researchers said, adding that those people carrying this version of the gene should respond normally to vaccines.

“(The study) shows that the way in which the lung responds to the infection is critical. This is important because most treatments have focussed on changing the way in which the immune system reacts to the virus,” said Professor James Davies, co-lead of the study.

The findings were published in the Nature Genetics journal.
 

spaminator

Hall of Fame Member
Oct 26, 2009
29,527
1,446
113
Pfizer says antiviral pill cuts risk of severe COVID-19 by 89%
Author of the article:Reuters
Reuters
Deena Beasley
Publishing date:Nov 05, 2021 • 15 hours ago • 4 minute read • 19 Comments
A 3D printed Pfizer logo is placed near medicines from the same manufacturer in this illustration taken September 29, 2021.
A 3D printed Pfizer logo is placed near medicines from the same manufacturer in this illustration taken September 29, 2021. PHOTO BY DADO RUVIC /REUTERS
Article content
Pfizer Inc’s experimental antiviral pill to treat COVID-19 cut by 89% the chances of hospitalization or death for adults at risk of severe disease, the company said on Friday, as its CEO vowed to make this promising new weapon in the fight against the pandemic available globally as quickly as possible.

Advertisement
STORY CONTINUES BELOW

Article content
The trial’s results suggest that the oral drug surpasses Merck & Co Inc’s pill, molnupiravir, which was shown last month to halve the risk of dying or being hospitalized for COVID-19 patients at high risk of serious illness.


Pfizer’s pill, with the brand name Paxlovid, could secure U.S. regulatory approval by the end of the year. The Pfizer trial was stopped early due to its high success rate. Full trial data is not yet available from either company.

President Joe Biden said the U.S. government has secured millions of doses of the Pfizer drug.

“If authorized by the FDA we may soon have pills that treat the virus in those who become infected,” Biden said. “The therapy would be another tool in our toolbox to protect people from the worst outcomes of COVID.”

Advertisement
STORY CONTINUES BELOW

Article content
Shares in Pfizer, which also makes one of the mostly widely used COVID-19 vaccines, were up 9% to $47.82, while Merck’s were down 9.3% to $82.09. Shares of vaccine makers took a hit, with Moderna Inc, Pfizer’s German partner BioNTech SE and Novavax all down 13-21%.

The pill is given in combination with an older antiviral called ritonavir. The treatment consists of three pills given twice daily. It has been in development for nearly two years.


The Pfizer and Merck pills are eagerly anticipated, with only limited options currently available for treating people sick with COVID-19.

Pfizer is in active discussions with 90 countries over supply contracts for its pill, Chief Executive Officer Albert Bourla said in an interview.

Advertisement
STORY CONTINUES BELOW

Article content
“Our goal is that everyone in the world would be able to have it as quickly as possible,” he said.

Bourla said that for high-income countries Pfizer expects to price its treatment close to where Merck has priced its pill. Merck’s U.S. contract price is around $700 for a five-day course of therapy. For low-income countries, Bourla said Pfizer is considering several options, with the goal of “no barrier for them as well to have access.”

Merck’s pill was approved by British regulators in a world first on Thursday.


Even with the potential offered by the Pfizer and Merck pills, preventing COVID-19 infections through broad use of vaccines remains the best way to control a pandemic that has killed more than 5 million people worldwide, including more than 750,000 in the United States, according to infectious disease experts.

Advertisement
STORY CONTINUES BELOW

Article content
“Vaccines are going to be the most effective and reliable tool that we have in this pandemic,” said Dr. Grace Lee, professor of pediatrics at Stanford University School of Medicine. “These oral medications are going to augment our ability to really reduce the risk of severe disease, hospitalization and death, which is huge, but it won’t prevent infection.”

While more than 7 billion vaccine doses have been administered worldwide, that has covered only about half the world’s people. In the United States, 58% of all people, including 70% of adults, are fully vaccinated. There are more than 400,000 new COVID-19 cases daily worldwide, with infections rising in 50 countries.

Mizuho analyst Vamil Divan forecast a “very minor impact” from the Pfizer drug on vaccination among people who do not want the vaccine or a booster shot as recommended by U.S. health regulators.

Advertisement
STORY CONTINUES BELOW

Article content
“I think there’s a small percentage of people that may decide not to get vaccinated, now that there are good treatment options,” Divan said.

Pfizer said it plans to submit interim trial results for its pill to the Food and Drug Administration (FDA) before the U.S. Thanksgiving holiday on Nov. 25.

The company said it expects to manufacture 180,000 treatment courses by the end of this year and at least 50 million courses by the end of next year, including 21 million in the first half of 2022. Bourla said that, based on the better-than-expected trial results, Pfizer is considering potentially doubling next year’s manufacturing target.

Antivirals need to be given as early as possible, before an infection takes hold, to be most effective.

Advertisement
STORY CONTINUES BELOW

Article content
The planned analysis of 1,219 patients in Pfizer’s study examined hospitalizations or deaths among people diagnosed with mild to moderate COVID-19 with at least one risk factor for developing severe disease, such as obesity or older age.

Among those given Pfizer’s drug within three days of symptom onset, the pill lowered the chances of hospitalization or death for adults at risk of developing severe COVID-19 by 89% compared to patients who received a placebo. Among these patients, 0.8% were hospitalized and none died by 28 days after treatment, compared to a 7% hospitalization rate and seven deaths in the placebo group.

Rates were similar for patients treated within five days of symptoms: 1% of the treatment group was hospitalized, compared to 6.7% for the placebo group, which included 10 deaths. Pfizer said that works out to being 85% effective at preventing hospitalization or death.

Two other trials – one in people without underlying risk factors and another in people who have been exposed to the virus but are not yet infected – are continuing and those results will likely be available in the first quarter of next year, Bourla said.

Pfizer did not detail side any effects but said adverse events happened in about 20% of both treatment and placebo patients. Possible side effects include nausea and diarrhea.

An FDA panel of outside experts is scheduled to meet Nov. 30 to discuss Merck’s pill. Pfizer said it did not know if Paxlovid would be reviewed at that meeting.
 
  • Like
Reactions: Twin_Moose

spaminator

Hall of Fame Member
Oct 26, 2009
29,527
1,446
113
WARMINGTON: New Pfizer COVID treatment may be easier pill to swallow
Author of the article:Joe Warmington
Publishing date:Nov 06, 2021 • 5 hours ago • 3 minute read • 6 Comments
Freedom Over Fear rally in Nathan Phillips Square in Toronto, Ont. on Saturday November 6, 2021.
Freedom Over Fear rally in Nathan Phillips Square in Toronto, Ont. on Saturday November 6, 2021. PHOTO BY ERNEST DOROSZUK /Toronto Sun/Postmedia
Article content
History has shown on the path to oblivion there are often off-ramps to avoid catastrophe.

Advertisement
STORY CONTINUES BELOW

Article content
Will Toronto take one in 2021?


With injections now heading to a third shot, creating acrimony on all sides of the vaccine debate, could a new coronavirus pill become a game-changer for battling COVID-19 and lowering the temperature on the fight over vaccine mandates?

“I think it is possible,” constitutional lawyer Rocco Galati said Saturday at Nathan Phillips Square during the first of two rallies for first responders fighting against mandatory vaccinations and firings. “Perhaps it could offer somewhat of a retreat.”

For the past year of this pandemic, it has been all advance for those pushing vaccines.

Maybe this is an olive branch?

It’s not the first opportunity like this presenting itself in this unusual time, with people facing termination from their careers.

Advertisement
STORY CONTINUES BELOW

Article content
Premier Doug Ford has thrown open a couple of back doors. First was the announcement the vaccine passport concept will wind down in early 2022. Then his government decided to not make vaccines mandatory for health-care workers.

Now, along comes news Pfizer is developing a promising pill that experts believe could reduce severe COVID-19 risk by 89%. This development follows a Merck pill that is also being tested.

Galati, who has been representing police officers, firefighters, paramedics and medical professionals not complying with vaccine status demands, still argues such stark orders are unconstitutional and immoral.

That said, any way to slow down segregating a portion of society is welcome news.

Toronto paramedic Scarlett Martyn (middle) and Toronto police officer Adrienne Gilvesy, talk with constitutional lawyer Rocco Galati at the Freedom Over Fear rally in Nathan Phillips Square in Toronto, Ont. on Saturday November 6, 2021. Both Martyn and Gilvesy are facing suspension and job termination for refusal to disclose vaccination status. Ernest Doroszuk/Toronto Sun/Postmedia
Toronto paramedic Scarlett Martyn (middle) and Toronto police officer Adrienne Gilvesy, talk with constitutional lawyer Rocco Galati at the Freedom Over Fear rally in Nathan Phillips Square in Toronto, Ont. on Saturday November 6, 2021. Both Martyn and Gilvesy are facing suspension and job termination for refusal to disclose vaccination status. Ernest Doroszuk/Toronto Sun/Postmedia
“They would still be able to make their money,” Galati said, referring to pharmaceutical companies.

Advertisement
STORY CONTINUES BELOW

Article content
And those facing dismissal could get a reprieve from the harsh measures. However, for most affected it’s really more a matter of principle than it is looking for a way out.’

Toronto Police Const. Adrienne Gilvesy and Toronto paramedic Scarlett Martyn were at the rally Saturday and indicated it’s about basic freedom and human rights for them.

They don’t believe government should be able to put a metaphorical gun to a person’s head and say: take this new medicine or face poverty.


In both of their cases, and in the case of Toronto firefighter Andrew Mason, who shared his story in Saturday’s Sun, we are dealing with high-performing professionals who you want in those jobs.

They have spent their careers keeping people safe and alive. They are not anti-vaxxers or conspiracy theorists but freethinking people reminding that bodily autonomy is a Canadian’s most basic right.

Advertisement
STORY CONTINUES BELOW

Article content
They may soon be unemployed because of their stance.

Mason is on unpaid suspension while Gilvesy is being investigated by Toronto Police Service’s professional standards unit. Martyn believes she will be suspended on her next shift Monday.


All three of these fine people have young children. They are not a risk to anybody. They are prepared to be tested before their shifts, but not to be strong-armed into disclosing their personal medical information.

In my view, it’s a mistake to fire any of them. They have all given too much to be discarded like garbage.

Galati believes one day a courtroom may adhere to the Charter of Rights and Freedoms and agree with them. But no matter what a court does, being this drastic on something so new is just plain mean.

Advertisement
STORY CONTINUES BELOW

Article content
There are other ways to handle this, especially when there’s so much leniency for others.

If prisoners are let out of jail, and there’s soft bail for violent offenders, and politicians can bend the rules, then there can be alternatives found to help our front-line heroes now labelled zeros.

After all, we’ve seen compromises routinely made for politicians who travelled during lockdowns or who helped a corporation sort out an ownership battle. There have also been senior police officers before the courts on criminal charges who are still paid their full salary while awaiting trial — sometimes for a decade.

It’s time to prescribe some middle-ground solutions, and perhaps this new Pfizer pill may be just what the doctor ordered.

jwarmington@postmedia.com
 
  • Like
Reactions: Twin_Moose